Does perioperative β-blocker exposure reduce 30-day all-cause mortality and cardiovascular morbidity in patients undergoing major noncardiac, nonvascular surgery?
Perioperative beta-blockade is associated with reduced 30-day mortality in patients undergoing major noncardiac, nonvascular surgery who have 2 or more Revised Cardiac Risk Index factors.
Among propensity-matched patients undergoing noncardiac, nonvascular surgery, perioperative β-blocker exposure was associated with lower rates of 30-day all-cause mortality in patients with 2 or more Revised Cardiac Risk Index factors. Our findings support use of a cumulative number of Revised Cardiac Risk Index predictors in decision making regarding institution and continuation of perioperative β-blockade. A multicenter randomized trial involving patients at a low to intermediate risk by these factors would be of interest to validate these observational findings.
London et al. (Wed,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: